Drug intelligence / Profile preview

cefotaxime + rifampin

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous, Oral, Intramuscular, Intrathecal

Overview

A combination antibiotic regimen consisting of cefotaxime (a third-generation cephalosporin) and rifampin (a rifamycin antibiotic). This combination demonstrates significant bactericidal activity against penicillin-resistant bacteria and multi-drug resistant strains, particularly Escherichia coli and Klebsiella pneumoniae. The combination has been shown to cause bacterial DNA fragmentation and maintain rifampin susceptibility in bacterial strains that would develop resistance to rifampin alone.

Targets

rpoB (DNA-directed RNA polymerase subunit beta)PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on cefotaxime + rifampin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefotaxime + rifampin.

Explore the full profile